RECENT NEWS
February, 2007: Everything Comes Down To Poo
A recent episode of NBC's Scrubs featured a song that we couldn't resist sharing. Click here to see for yourself!
January, 2007: Fears over deadly hospital bugs
The deadly Clostridium difficile hospital bug is on the rise, while MRSA superbug rates are falling too slowly to meet government targets. Read more
January, 2007: TECHLAB® will be exhibiting at the following conferences in 2007:
American Society for Microbiology
Toronto, Canada, May 22-24
Booth #834
June, 2006: TECHLAB®, Inc. announces FDA clearance of two new diagnostic tests
The ASCA-CHEK is an ELISA for the detection of anti-Saccharomyces cerevisiae antibodies (ASCA) as a marker for Crohn's disease. An estimated 1 million Americans suffer from inflammatory bowel disease (IBD), which is comprised of Crohn's disease and ulcerative colitis. These two distinct diseases require rapid, accurate diagnosis to optimize treatment; conventional methods may take years to confirm a diagnosis. Unlike serum ASCA tests, the ASCA-CHEK is designed for use on fecal specimens and cleared for use in adult and pediatric patients, making it an attractive, non-invasive alternative. The ASCA-CHEK provides a highly specific method for distinguishing Crohn's disease from other inflammatory gastrointestinal diseases. Read more
May, 2006: Inverness Medical Innovations to Acquire Minority Interest in TECHLAB®, Inc.
WALTHAM, Mass., May 18, 2006 - Inverness Medical Innovations, Inc. (Amex: IMA) today announced that it will acquire 49% of the capital stock of TECHLAB®, Inc., a privately held diagnostics company, in exchange for 303,417 shares of Inverness common stock. TECHLAB® develops, manufactures, and distributes rapid non-invasive intestinal diagnostics tests in the areas of intestinal inflammation, antibiotic associated diarrhea and parasitology.
The transaction provides Inverness, whose Wampole subsidiary already distributes TECHLAB's products in the United States, with exclusive global distribution rights to TECHLAB's market leading line of enteric disease testing products, as well as future human medical diagnostic products, as TECHLAB's existing global distribution relationships lapse. These products include both ELISA and rapid format assays for the detection of C. difficile Toxins A&B, a rapidily growing world-wide market segment. TECHLAB®, Inc. works with major universities in the development of new tests for intestinal parasites for use in both industrialized and developing countries.
TECHLAB®, Inc. has developed and now, with access to Inverness' intellectual property, expects to commence selling the only US FDA-cleared rapid membrane assay to detect fecal lactoferrin, a test that can help differentiate bacterial enteric infections and inflammatory bowel diseases from maladies such as irritable bowel syndrome and diverticulitis. In the US alone, there are over 3 million cases of Crohn's Disease, 4 million cases of ulcerative colitis and 10 million cases of irritable bowel syndrome reported annually. Additionally, TechLab has a pipeline of products in development representing opportunities for Inverness in both the professional and consumer marketplaces.
TECHLAB®, Inc. will continue to operate with the current executive management team of Tracy Wilkins, Ph.D. as president, David Lyerly, Ph.D. as Vice President of Research and Development and David Wall as VP of Operations.
Diarrhea Digest
Stay up-to-date with the Diarrhea Digest, an irregular publication of TECHLAB® dedicated to the etiology, diagnosis, and therapy of diarrheal diseases and related aspects of intestinal ecology.
Not familiar with the Diarrhea Digest? View our latest issue.